1. Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy.
- Author
-
Xiaofei Zhou, Yuetang Zhuang, Xiaohong Liu, Yaowen Gu, Junting Wang, Yuchen Shi, Li Zhang, Rui Li, Yelin Zhao, Hebing Chen, Jiao Li, Hongjuan Yao, and Liang Li
- Subjects
- *
PANCREATIC cancer , *NANOMEDICINE , *EXOSOMES , *LIPOSOMES , *DASATINIB , *ANALYSIS of variance , *CANCER treatment - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death. Therefore, we intend to explore novel strategies against PDAC. The exosomes-based biomimetic nanoparticle is an appealing candidate served as a drug carrier in cancer treatment, due to its inherit abilities. In the present study, we designed dasatinib-loaded hybrid exosomes by fusing human pancreatic cancer cells derived exosomes with dasatinib-loaded liposomes, followed by characterization for particle size (119.9 ± 6.10 nm) and zeta potential (-11.45 ± 2.24 mV). Major protein analysis from western blot techniques reveal the presence of exosome marker proteins CD9 and CD81. PEGylated hybrid exosomes showed pH-sensitive drug release in acidic condition, benefiting drug delivery to acidic cancer environment. Dasatinib-loaded hybrid exosomes exhibited significantly higher uptake rates and cytotoxicity to parent PDAC cells by two-sample t-test or by one-way ANOVA analysis of variance, as compared to free drug or liposomal formulations. The results from our computational analysis demonstrated that the drug-likeness, ADMET, and protein-ligand binding affinity of dasatinib are verified successfully. Cancer derived hybrid exosomes may serve as a potential therapeutic candidate for pancreatic cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF